Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives

European Journal of Medicinal Chemistry

Volumn 49, Issue , 2012, Pages 343-353

  Legoabe, Lesetja J ^a   Petzer, Anél ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Chromone; Competitive inhibition; Molecular docking; Monoamine oxidase; Reversible inhibition; Structure activity relationship

Indexed keywords

3 [[(4 OXO 4H CHROMEN 6 YL)OXY]METHYL]BENZONITRILE; 4 [[(4 OXO 4H CHROMEN 6 YL)OXY]METHYL]BENZONITRILE; 6 (2 PHENYLETHOXY) 4H CHROMEN 4 ONE; 6 (BENZYLOXY) 4H CHROMEN 4 ONE; 6 32 PHENYLPROPOXY) 4H CHROMEN 4 ONE; 6 [(3 BROMOBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(3 CHLOROBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(3 FLUOROBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(3 METHYLBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(4 BROMOBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(4 CHLOROBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(4 FLUOROBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [(4 METHYLBENZYL)OXY] 4H CHROMEN 4 ONE; 6 [2 (4 BROMOPHENYL)ETHOXY] 4H CHROMEN 4 ONE; 6 [[4 (TRIFLUOROMETHYL)BENZYL]OXY] 4H CHROMEN 4 ONE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CHROMONE DERIVATIVE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MOLECULAR DOCKING; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

CATALYTIC DOMAIN; CHROMONES; HUMANS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857237219     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.01.037     Document Type: Article

References (39)

1. M.B.H. Youdim, and Y.S. Bakhle Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness Br. J. Pharmacol. 147 2006 S287 S296 (Pubitemid 43077287)
2. M.B.H. Youdim, D.E. Edmondson, and K.F. Tipton The therapeutic potential of monoamine oxidase inhibitors Nat. Rev. Neurosci. 7 2006 295 309
3. A.A. Boulton Phenylethylaminergic modulation of catecholaminergic neurotransmission Prog. Neuropsychopharmacol. Biol. Psychiatry 15 1991 139 156
4. F. Lasbennes, R. Sercombe, and J.J. Seylaz Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: relevance to the blood-brain barrier Cereb. Blood Flow. Metab. 3 1983 521 528 (Pubitemid 14182297)
5. M. Da Prada, G. Zürcher, I. Würthrich, and W.E. Haefely On tyramine, food beverages and the reversible MAO inhibitor moclobemide J. Neural Tansm. 26 1988 33 56
6. M.B.H. Youdim, and M. Weinstock Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation Neurotoxicology 25 2004 243 250 (Pubitemid 38044185)
7. P. Riederer, L. Lachenmayer, and G. Laux Clinical applications of MAO-inhibitors Curr. Med. Chem. 11 2004 2033 2043 (Pubitemid 38967728)
8. S.E. Zisook Clinical overview of monoamine oxidase inhibitors Psychosomatics 26 1985 240 251
9. H.H. Fernandez, and J.J. Chen Monoamine oxidase-B inhibition in the treatment of Parkinson's disease Pharmacotherapy 27 2007 174S 185S (Pubitemid 350234307)
10. J.P. Finberg, J. Wang, K. Bankiewich, J. Harvey-White, I.J. Kopin, and D.S. Goldstein Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey J. Neural Transm. 52 1998 279 285
11. D.A. Di Monte, L.E. DeLanney, I. Irwin, J.E. Royland, P. Chan, M.W. Jacowec, and J.W. Langston Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys Brain Res. 738 1996 53 59 (Pubitemid 26379645)
12. J.P. Finberg, I. Lamensdorf, and T. Armoni Modification of dopamine release by selective inhibitors of MAO-B Neurobiology (Bp) 8 2000 137 142
13. R.N. Kalaria, M.J. Mitchell, and S.I. Harik Monoamine oxidases of the human brain and liver Brain 111 1988 1441 1451 (Pubitemid 19028462)
14. G.G.S. Collins, M. Sandler, E.D. Williams, and M.B.H. Youdim Multiple forms of human brain monoamine oxidase Nature 225 1970 817 820
15. M. Gesi, A. Santinami, R. Ruffoli, G. Conti, and F. Fornai Novel aspects of dopamine oxidative metabolism confounding outcomes take place of certainities Pharmacol. Toxicol. 89 2001 217 224 (Pubitemid 33070921)
16. F. Fornai, G. Battaglia, M. Gesi, F.S. Giorgi, F. Orzi, and F. Nicoletti Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity Brain Res. 887 2000 110 117 (Pubitemid 32008029)
17. S.A. Marchitti, R.A. Deitrich, and V. Vasiliou Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase Pharmacol. Rev. 59 2007 125 150 (Pubitemid 46855437)
18. I. Lamensdorf, G. Eisenhofer, J. Harvey-White, A. Nechustan, K. Kirk, and I.J. Kopin 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells Brain Res. 868 2000 191 201 (Pubitemid 30347515)
19. W.J. Burke, V.B. Kumar, N. Pandey, W.M. Panneton, Q. Gan, M.W. Franko, M. O'Dell, S.W. Li, Y. Pan, H.D. Chung, and J.E. Galvin Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathol. 115 2008 193 203
20. J.K. Mallajosyula, D. Kaur, S.J. Chinta, S. Rajagopalan, A. Rane, D.G. Nicholls, D.A. Di Monte, H. Macarthur, J.K. Andersen, and B. MAO Elevation in mouse brain astrocytes results in Parkinson's pathology PloS One 3 2008 e1616
21. A. Nicotra, F. Pierucci, H. Parvez, and O. Santori Monoamine oxidase expression during development and aging Neurotoxicology 25 2004 155 165 (Pubitemid 38044177)
22. J.S. Fowler, N.D. Volkow, G.J. Wang, J. Logan, N. Pappas, C. Shea, and R. MacGregor Age-related increases in brain monoamine oxidase B in living healthy human subjects Neurobiol. Aging 18 1997 431 435 (Pubitemid 27435085)
23. C. Gnerre, M. Catto, F. Leonetti, P. Weber, P.-A. Carrupt, C. Altomare, A. Carotti, and B. Testa Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs J. Med. Chem. 43 2000 4747 4758 (Pubitemid 32002686)
24. A. Gaspar, T. Silva, M. Yáñez, D. Viña, F. Orallo, F. Ortuso, E. Uriarte, S. Alcaro, and F. Borges Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors J. Med. Chem. 54 2011 5165 5173
25. A. Gaspar, J. Reis, A. Fonseca, N. Milhazes, D. Viña, E. Uriarte, and F. Borges Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors Bioorg. Med. Chem. Lett. 21 2011 707 709
26. L. Novaroli, M. Reist, E. Favre, A. Carotti, M. Catto, and P.A. Carrupt Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening Bioorg. Med. Chem. 13 2005 6212 6217 (Pubitemid 41400144)
27. B. Strydom, S.F. Malan, N. Castagnoli Jr. , J.J. Bergh, and J.P. Petzer Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues Bioorg. Med. Chem. 18 2010 1018 1028
28. L.H.A. Prins, J.P. Petzer, and S.F. Malan Inhibition of monoamine oxidase by indole and benzofuran derivatives Eur. J. Med. Chem. 45 2010 4458 4466
29. K.F. Tipton, S. Boyce, J. O'Sullivan, G.P. Davey, and J. Healy Monoamine oxidases: certainties and uncertainties Curr. Med. Chem. 11 2004 1965 1982 (Pubitemid 38967723)
30. J.S. Fowler, N.D. Volkow, J. Logan, G. Wang, R.R. MacGregor, D. Schlyer, A.P. Wolf, N. Pappas, D. Alexoff, C. Shea, E. Dorflinger, L. Kruchowy, K. Yoo, E. Fazzini, and C. Patlak Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal Synapse 18 1994 86 93 (Pubitemid 24308128)
31. C.I. Manley-King, J.J. Bergh, and J.P. Petzer Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues Bioorg. Med. Chem. 19 2011 261 274
32. S.-Y. Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, and T. Tsukihara Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors Proc. Natl. Acad. Sci. U.S.A. 105 2008 5739 5744 (Pubitemid 351758442)
33. C. Binda, P. Newton-Vinson, F. Hubálek, D.E. Edmondson, and A. Mattevi Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders Nat. Struct. Biol. 9 2002 22 26 (Pubitemid 34049174)
34. D.E. Edmondson, A. Mattevi, C. Binda, M. Li, and F. Hubalek Structure and mechanism of monoamine oxidase Curr. Med. Chem. 11 2004 1983 1993 (Pubitemid 38967724)
35. D.E. Edmondson, C. Binda, J. Wang, A.K. Upadhyay, and A. Mattevi Molecular and mechanistic properties of membrane-bound mitochondrial monoamine oxidase Biochemistry 48 2009 4220 4230
36. C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D.E. Edmondson, and A. Mattevi Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs J. Med. Chem. 50 2007 5848 5852 (Pubitemid 350106038)
37. Accelrys Discovery Studio 1.7 2006 Accelrys Software Inc. San Diego, CA, USA http://www.accelrys.com
38. F. Hubálek, C. Binda, A. Khalil, M. Li, A. Mattevi, N. Castagnoli, and D.E. Edmondson Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors J. Biol. Chem. 280 2005 15761 15766 (Pubitemid 40616695)
39. W.L. DeLano The PyMOL Molecular Graphics System 2002 DeLano Scientific San Carlos, USA